WO1996013267A3 - Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma - Google Patents
Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma Download PDFInfo
- Publication number
- WO1996013267A3 WO1996013267A3 PCT/US1995/013624 US9513624W WO9613267A3 WO 1996013267 A3 WO1996013267 A3 WO 1996013267A3 US 9513624 W US9513624 W US 9513624W WO 9613267 A3 WO9613267 A3 WO 9613267A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- brimonidine
- glaucoma
- derivatives
- prostaglandins
- Prior art date
Links
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 title abstract 2
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- 229960003679 brimonidine Drugs 0.000 title abstract 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 title abstract 2
- 150000003180 prostaglandins Chemical class 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 239000000464 adrenergic agent Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 230000004406 elevated intraocular pressure Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000004410 intraocular pressure Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention concerns combinations of alpha adrenergic agents such as brimonidine and its derivatives as represented by formula (I) wherein each Y is independently selected from the group consisting of N, N-CH3, O, S and C-R1; R1 is hydrogen, lower alkyl or oxo; R2, R3 and R4 are independently selected from the group consisting of hydrogen, halogen, lower alkyl and lower alkenyl; n is an integer from 1 to 3; and a broken line beside a solid line indicates either a single or a double bond with the proviso that when n=1, both bonds from Y to C-R1 cannot be double bonds, and prostaglandins known in the art to cause lowering of intraocular pressure which are useful in compositions, methods of treatment and articles of manufacture for the treatment of glaucoma and alleviation of elevated intraocular pressure.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33005094A | 1994-10-27 | 1994-10-27 | |
| US08/330,050 | 1994-10-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996013267A2 WO1996013267A2 (en) | 1996-05-09 |
| WO1996013267A3 true WO1996013267A3 (en) | 1996-07-04 |
Family
ID=23288106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1995/013624 WO1996013267A2 (en) | 1994-10-27 | 1995-10-20 | Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1996013267A2 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US5856329A (en) * | 1995-06-28 | 1999-01-05 | Allergan | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
| WO1998020881A1 (en) | 1996-11-12 | 1998-05-22 | Alcon Laboratories, Inc | 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension |
| EP0968183A2 (en) | 1997-03-07 | 2000-01-05 | Alcon Laboratories, Inc. | 13-thia prostaglandins for use in glaucoma therapy |
| WO2004073708A1 (en) * | 1998-12-17 | 2004-09-02 | Dean Thomas R | Brinzolamide and brimonidine for treating ocular conditions |
| US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| EP2329849B1 (en) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
| US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| WO2011117378A2 (en) | 2010-03-26 | 2011-09-29 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of telangiectasia |
| KR101707704B1 (en) | 2010-03-26 | 2017-02-16 | 갈데르마 리써어치 앤드 디벨로프먼트 | Improved methods and compositions for safe and effective treatment of erythema |
| US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
| BR112013009578B1 (en) | 2010-10-21 | 2020-10-20 | Galderma S.A. | topical gel composition and use of a topical gel composition |
| US20130023536A1 (en) * | 2011-07-20 | 2013-01-24 | Graham Richard S | Fixed dose combination of bimatoprost and brimonidine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994008585A1 (en) * | 1992-10-13 | 1994-04-28 | Alcon Laboratories, Inc. | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma |
-
1995
- 1995-10-20 WO PCT/US1995/013624 patent/WO1996013267A2/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994008585A1 (en) * | 1992-10-13 | 1994-04-28 | Alcon Laboratories, Inc. | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma |
Non-Patent Citations (1)
| Title |
|---|
| SERLE JB: "Pharmacological advances in the treatment of glaucoma.", DRUGS AGING, SEP 1994, 5 (3) P156-70, NEW ZEALAND * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996013267A2 (en) | 1996-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1996013267A3 (en) | Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma | |
| EP1225168A3 (en) | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | |
| TR200003844T2 (en) | Epothilone derivatives, their synthesis and uses | |
| MY121967A (en) | New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency | |
| GEP20115347B (en) | Heterocyclocarboxamide derivatives | |
| IL157773A0 (en) | 2-amino-propanol derivatives | |
| BG103485A (en) | Ketobanzamides as calpain inhibitors | |
| MY113022A (en) | Novel pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present | |
| AU688628B2 (en) | Novel amidinonaphthyl derivative or salt thereof | |
| MXPA03004165A (en) | Rubber compounds that contain gels and inorganic peroxides. | |
| AU3192195A (en) | Thiazolidinedione derivatives, their production and use | |
| WO1996013259A3 (en) | Method and compositions for inhibiting protein kinases | |
| CA2416867A1 (en) | Cyclopentanoindoles, compositions containing such compounds and methods of treatment | |
| CA2057464A1 (en) | Terpolymers of ethylene, their preparation and their use as additives for mineral oil distillates | |
| HU9503401D0 (en) | Novel 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazole derivatives | |
| CA2221110A1 (en) | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension | |
| EP0437030A3 (en) | Use of 4-substituted imidazoles for lowering intraocular pressure | |
| HK1049479A1 (en) | Ocular hypotensive lipids | |
| NZ506497A (en) | Indole derivatives, pharmaceuticals thereof and their use in lowering intraocular pressure or for the treatment or prevention of glaucoma or ocular hypertension | |
| TW427913B (en) | Eye drop composition comprising pilocarpine and a β-blocking agent and process making the same | |
| MY132550A (en) | Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists | |
| CA2048010A1 (en) | Proline derivatives | |
| AU6597790A (en) | Use of 6- or 7-hydroxyindole derivatives as couplers and dyeing compositions and methods using these | |
| MY100512A (en) | New 6-or 7-methlenandrosta-1, 4-diene-3, 17-dione derivatives and process for their preparation. | |
| WO2004019874A3 (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |